Journal September 16, 2026 6 min read

MOTS-c: What It Is Studied Alongside

MOTS-c is a mitochondrial-derived peptide studied in metabolic, inflammatory, cardiovascular and immune contexts. This page maps the mechanisms, tissues and models it is investigated with, and flags where the evidence is

peptides-pro Editorial

MOTS-c is the mitochondrial open reading frame of the 12S rRNA type-c, a peptide encoded within the mitochondrial 12S rRNA gene. It is also written mitochondrial open-reading frame of the 12S rRNA-c, and is classed as a mitochondrial-derived peptide (MDP) or mitokine; the same literature describes it as a mitochondrial-encoded host defense peptide (HDP) [1]. The evidence block does not give a sequence, formula or molecular weight for the wild-type peptide, so none is stated here. The work centres on AMPK-linked metabolic signalling and on mitochondrial redox and inflammasome pathways, with the peptide acting through intracrine, paracrine and endocrine routes [11].

MOTS-c is studied alongside a defined set of partners: the NLRP3 inflammasome, the LAT1 amino-acid transporter, Nrf2-dependent antioxidant signalling, mitochondrial subpopulation bioenergetics, and the related mitochondrial-derived peptide humanin. The sections below set out what has been reported for each, and name the population or model in which the observation was made.

Research Studies

MOTS-c and antibacterial host defense in vitro

MOTS-c was identified as a mitochondrial-encoded amphipathic and cationic peptide with direct antibacterial and immunomodulatory functions, consistent with the chemistry and behaviour of known host defense peptides. In that work the peptide targeted Escherichia coli, and the authors proposed that it derives from the primordial proto-mitochondrial bacteria [1]. This is an in vitro and sequence-based finding; it does not establish an antibacterial role in animals or in humans.

MOTS-c and NLRP3 inflammasome activity in a diabetic rat model

In a high-fat diet and streptozotocin-induced type 2 diabetes rat model, MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein, and selectively modulated plasma inflammatory mediators, with suppression of systemic and cardiac NLRP3 inflammasome activation [2]. The model is animal-only. The reported effects are on inflammasome readouts and glycaemia in rats, not clinical endpoints.

MOTS-c and LAT1-mediated uptake in radiation-induced lung injury

Wild-type MOTS-c is highly polar and poorly membrane-permeable. Substituting the polar arginine at position 13 with alanine gave R13A-MOTS-c, raising the hydrophobicity index from -0.938 to -0.544 and measurably improving cellular uptake. Competition with canonical LAT1 substrates (leucine, BCH) and LAT1 knockdown confirmed that R13A-MOTS-c enters cells via LAT1-mediated transport, and the engineered peptide attenuated radiation-induced lung injury via Nrf2 activation and mitochondrial protection [4]. The wild-type sequence given in that report is Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. The uptake and injury findings are experimental; the R13A analogue is an engineered research reagent, not the wild-type peptide.

MOTS-c and humanin in atrial fibrillation

Humanin and MOTS-c expression in human atrial tissue was analysed using public GEO data, immunohistochemistry and immunofluorescence, and plasma levels were measured; therapeutic potential and mechanisms were then evaluated in an AngII-induced mouse model and in primary cardiac cells [5]. The study reports that both peptides attenuate atrial fibrillation by suppressing fibrosis and mitochondrial dysfunction. Human tissue expression and plasma measurements are observational; the interventional evidence is from mice and primary cells.

MOTS-c and myocardial ischemia-reperfusion injury in acute myocardial infarction

Seventy-two patients with acute myocardial infarction undergoing percutaneous coronary intervention were divided into MIRI (n = 34) and non-MIRI (n = 38) groups, and MOTS-c levels were measured in peripheral serum and intracoronary blood alongside clinical data [6]. This is a cross-sectional association study in patients; it reports a relationship between serum MOTS-c and myocardial ischemia-reperfusion injury and does not establish that the peptide causes the observed difference.

MOTS-c and thyroid autoimmunity in Hashimoto's thyroiditis

In a cross-sectional study, 90 patients diagnosed with Hashimoto's thyroiditis were compared with age- and sex-matched healthy controls, and circulating MOTS-c levels were related to thyroid autoimmunity and metabolic regulation [3]. The authors report reduced circulating MOTS-c in Hashimoto's thyroiditis, interpreting this as reflecting integrated autoimmune and metabolic dysregulation. The design is cross-sectional and cannot separate cause from consequence.

MOTS-c and the m.1382A>C polymorphism in polycystic ovary syndrome

MOTS-c is associated with reduced insulin resistance and obesity, and the m.1382A>C polymorphism of the MOTS-c gene has been linked to increased type 2 diabetes risk in men. One study examined serum MOTS-c levels in adolescents with and without polycystic ovary syndrome and evaluated the association between the polymorphism and serum levels in that population [7]. The population is adolescents with PCOS; the findings are genetic and cross-sectional.

MOTS-c and anaesthetic technique in renal transplantation

A prospective controlled trial compares sevoflurane general anaesthesia with combined spinal-epidural anaesthesia for effects on ferroptosis and on humanin and MOTS-c levels in kidney transplant recipients, in the context of ischemia-reperfusion injury and graft function [8]. This is a registered trial record; results are not reported in the evidence block, so no outcome is stated here.

MOTS-c and mesenchymal stromal cell reparative function

MOTS-c activates metabolic signalling but blunts reparative function in human mesenchymal stromal cells, a setting in which obesity compromises MSC metabolism and reparative capacity [10]. The finding is in human MSCs and is relevant to cell-therapy research rather than to whole-organism effects.

MOTS-c and cardiac ischemia-reperfusion injury

MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia-reperfusion injury, a setting where mitochondrial dysfunction drives injury through impaired bioenergetics, oxidative stress and disrupted mitochondrial homeostasis [12]. This is a mechanistic, preclinical line of work.

MOTS-c and sepsis-induced cardiomyopathy

Sepsis-induced cardiomyopathy is characterised by inflammatory dysregulation, mitochondrial dysfunction, metabolic disturbance and changes in the myocardial microenvironment, and MOTS-c has been reviewed in that context for its mechanisms and translational potential [9]. This is a review; it synthesises proposed mechanisms rather than reporting a new experiment.

MOTS-c and inflammatory lung disease

MOTS-c is described as a secreted mitochondrial microprotein with intracrine, paracrine and endocrine effects across multiple tissues; although first described as a regulator of metabolic homeostasis, evidence indicates it also modulates oxidative and inflammatory pathways relevant to inflammatory lung diseases [11]. This is a review of translational potential.

Comparison of study contexts

Context	Population or model	Primary readout
Antibacterial host defense [1]	In vitro, E. coli	Direct antibacterial and immunomodulatory activity
Type 2 diabetes [2]	High-fat diet and streptozotocin rat model	Fasting glucose, CRP, NLRP3 inflammasome
Radiation-induced lung injury [4]	Engineered R13A-MOTS-c, LAT1-dependent uptake	Nrf2 activation, mitochondrial protection
Atrial fibrillation [5]	Human atrial tissue; AngII mouse model; primary cardiac cells	Fibrosis, mitochondrial dysfunction
Myocardial ischemia-reperfusion injury [6]	72 AMI patients after PCI	Serum and intracoronary MOTS-c levels
Hashimoto's thyroiditis [3]	90 patients vs matched controls	Circulating MOTS-c
Polycystic ovary syndrome [7]	Adolescents with and without PCOS	Serum MOTS-c, m.1382A>C genotype
Renal transplantation [8]	Registered prospective trial	Ferroptosis, humanin and MOTS-c levels

Across these contexts the recurring partners are the NLRP3 inflammasome, LAT1 transport, Nrf2-linked antioxidant signalling, mitochondrial bioenergetics and genome integrity, and humanin. Where the evidence is animal-only or in vitro, that is stated in the relevant section; the human data in the block are cross-sectional or observational.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing here is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.